Integrating CD8 and CD4 effector neo-epitope content with regulatory T cell epitope exclusion is a superior prognostic biomarker for bladder cancer patients compared to their tumor mutation burden

by | Nov 11, 2019 | 0 comments

EpiVax_Oncology_SITC19_BLCA_06Nov19_50Wx36H

 

Submit a Comment

Your email address will not be published. Required fields are marked *